ubrogepant
ubrogepant: developed by 1 company · 4 clinical trials tracked · 1 FDA decision.
ubrogepant evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could ubrogepant → ABBV affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| AbbVie Inc. (ABBV) Migraine; Healthy Volunteer | Phase 3 |
Clinical Trials (4)
A Two-Part, Phase 1, Open-Label, Randomized Study to Evaluate the Relative Bioavailability (Versus Immediate Release Tablet) and Food Effect of a New Orally Disintegrating Tablet Formulation of Ubrogepant in Healthy Volunteers
Primary endpoint: Number of Participants Experiencing Adverse Events
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension
Primary endpoint: Change From Baseline in Number of Migraine Days Occurring During Perimenstrual Periods (PMPs) Across the Double-Blind Treatment Period
Migraine Medication Effects on Urinary Symptoms
Primary endpoint: changes in OAB symptoms
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17)
Primary endpoint: Percentage of participants with Pain Freedom at 2 Hours After the Initial Dose in pediatric participants aged 6 to 17 years
Frequently asked questions
Who is developing ubrogepant?
ubrogepant is being developed by AbbVie Inc..
How many clinical trials involve ubrogepant?
BioSniper tracks 4 clinical trials involving ubrogepant.
What is ubrogepant's latest FDA decision?
The most recent tracked FDA decision for ubrogepant is Approval, dated December 23, 2019.